A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
News|Articles|August 1, 2025
Top 5 women's health headlines you missed in July 2025
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
Take a quick look at everything you may have missed last month, including the latest FDA updates, top stories, and exclusive interviews.
Advertisement
Advertisement
July 2025 brought a wave of important updates that continue to shape the care of women across all stages of life.
Related to this article
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
The FDA accepted an sNDA and granted priority review for elinzanetant to treat VMS in women receiving endocrine therapy to treat or prevent HR+ breast cancer.
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
A review finds post-miscarriage ultrasound heterogeneity is common and that symptoms, not endometrial thickness, should guide management after EPL.
Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.
Advertisement
Advertisement